Anti-SNX25 antibody [EPR9122]
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(1 Publication)
Rabbit Recombinant Monoclonal SNX25 antibody. Suitable for WB and reacts with Human samples. Cited in 1 publication.
View Alternative Names
MSTP043, SNX25, Sorting nexin-25
- WB
Unknown
Western blot - Anti-SNX25 antibody [EPR9122] (AB140655)
All lanes:
Western blot - Anti-SNX25 antibody [EPR9122] (ab140655) at 1/1000 dilution
Lane 1:
Jurkat cell lysate at 10 µg
Lane 2:
Raji cell lysate at 10 µg
Secondary
All lanes:
Goat anti-rabbit HRP at 1/2000 dilution
Predicted band size: 98 kDa
Observed band size: 98 kDa
false
Related conjugates and formulations (1)
-
Anti-SNX25 antibody [EPR9122] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purity
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (1)
Recent publications for all applications. Explore the full list and refine your search
International journal of oral science 17:34 PubMed40246825
2025
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com